Ultraceuticals
Tailored Scientific Solutions

Reimagining the
Discovery-to-Market Journey

Ultraceuticals empowers pharmaceutical, biotech, and research organizations through AI-driven platforms that accelerate discovery, repurposing, and validation.

Automated Virtual High-Throughput Screen & Concentration Response
Automated In Silico 384-Well Robotic Assay
384-Well In Silico Plate ReaderSelected Lead: Sub-nanomolar Potency Confirmed
ENTERPRISE AUTOMATION

Pharmaceutical Enterprises

Accelerate new drug discovery and validation with AI automation. Our integrated pipeline delivers predictive accuracy, reduced R&D cycle times, and real-world validation, helping pharma teams advance from lead molecules to Investigational New Drug (IND) filings up to 90% faster.

Solution Value Drivers:
High-throughput virtual screening of 10^60 chemical space
Target validation and mechanism-of-action plausibility reports
Preemptive solid-state stability & excipient formulation audit
Paragraph IV and Freedom-to-Operate regulatory dossiers
Schedule Pharma Consultation
AGILE R&D ACCELERATION

Biotechnology Firms & CROs

Empower biopharma innovation with scalable, cloud-based AI experimentation. Ultraceuticals' hybrid platform helps emerging biotechs explore novel macrocycles, optimize formulation kinetics, and resolve complex protein conformations without multi-million-dollar wet-lab overhead.

Solution Value Drivers:
Rapid de novo candidate design within 48-hour sprints
Sub-angstrom protein conformation predictions via FoldPredict
Contrastive drug repurposing across 1.8M interactome nodes
Flexible private VPC, SaaS, or on-premises deployment
Explore Biotech Integration
UASPIRE ALLIANCE

Academic & Research Institutes

Enhance research productivity and structural data accuracy. Through our UASPIRE program, we provide collaborative access to DiscoveraAI and ReviveAI for research universities, advancing breakthroughs in neurodegenerative diseases, oncology, and microbial resistance.

Solution Value Drivers:
Joint research grant applications & co-authorship
Access to GPU-accelerated molecular dynamics clusters
Enriching PhD & post-graduate research fellowships
Multi-omics integration across public and private bio-banks
Join UASPIRE Alliance
STRATEGIC CO-DEVELOPMENT

Institutional Investors & Co-Developers

Partner with an AI-first neo-biotech company with 4 years of proven deeptech maturation. Our active internal pipeline assets (ALS CHIT1, BioFilm Omni, stabilized oncology formulations) offer de-risked licensing and high-value co-development opportunities.

Solution Value Drivers:
Validated preclinical in vivo milestones across proprietary assets
Clean Freedom-to-Operate landscape with filed IP portfolios
Substantially reduced clinical trial failure rates via AI de-risking
HIPAA-isolated sovereign infrastructure ready for commercial scale
Access Data Room
Enterprise Security & Compliance

Zero Trust Architecture Governs Every Solution

No data is trusted by default. Every computation, model transfer, and chemical structure is encrypted, monitored with multi-layered authentication, and strictly isolated within HIPAA-compliant sovereign enclaves.

Review Security Whitepaper